Advanced Biomedical Technologies Inc. (ABMT) Financial Statements (2023 and Earlier)

Company Profile

Business Address 200 PARK AVENUE, SUITE 1700
NEW YORK, NY 10166
State of Incorp.
Fiscal Year End October 31
Industry (SIC) 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

7/31/2021
TTM
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 2026777
Cash and cash equivalents 2026777
Inventory, net of allowances, customer advances and progress billings 10064   
Inventory 10064   
Prepaid expense    1720
Other undisclosed current assets 295033  
Total current assets: 331119402527
Noncurrent Assets
Operating lease, right-of-use asset 33 
Property, plant and equipment 105991036172
Other undisclosed noncurrent assets     1
Total noncurrent assets: 138991036174
TOTAL ASSETS: 46921914285101
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Due to related parties 4,7064,9174,3263,7673,084
Other liabilities   443409338
Other undisclosed current liabilities 3,1581,7809939041,042
Total current liabilities: 7,8646,6975,7615,0804,463
Noncurrent Liabilities
Long-term debt and lease obligation 7    
Operating lease, liability 7 
Total noncurrent liabilities: 14    
Total liabilities: 7,8786,6975,7615,0804,463
Commitments and contingencies     1
Stockholders' equity
Stockholders' equity attributable to parent, including: (7,402)(6,478)(5,619)(4,995)(4,362)
Common stock 11111
Additional paid in capital 2,8242,7682,7402,6742,521
Accumulated other comprehensive income 2133427310104
Accumulated deficit (10,256)(9,581)(8,633)(7,679)(6,988)
Other undisclosed stockholders' equity attributable to parent 8    
Total stockholders' equity: (7,402)(6,478)(5,619)(4,995)(4,362)
Other undisclosed liabilities and equity (7)   (1)
TOTAL LIABILITIES AND EQUITY: 46921914285101

Income Statement (P&L) ($ in thousands)

7/31/2021
TTM
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
Revenues 12412   
Revenue from related parties 111  
Cost of revenue (52)(8)   
Gross profit: 724   
Operating expenses (518)(609)(634)(404)(461)
Operating loss: (447)(605)(634)(404)(461)
Nonoperating expense (225)(344)(19)(30)(14)
Other nonoperating expense (22)(18)(19)(30)(14)
Interest and debt expense (14)(13)(14)(16)(249)
Loss from continuing operations before equity method investments, income taxes: (686)(962)(667)(449)(725)
Other undisclosed income (loss) from continuing operations before income taxes 1413(287)(242) 
Net loss available to common stockholders, diluted: (672)(949)(953)(692)(725)

Comprehensive Income ($ in thousands)

7/31/2021
TTM
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
Net loss: (672)(949)(953)(692)(725)
Other comprehensive income (loss) (313)62263(94)252
Comprehensive loss, net of tax, attributable to parent: (985)(887)(691)(786)(472)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: